Suppose you were a drug company, and you’ve invented a new drug. It’s OK, but it’s no better than the competition. How do you convince people to buy it?
You need a selling point – something that sets your product apart. Fortunately, with drugs, you have plenty of options. You could look into the pharmacology – the chemistry of how your drug works in the body – and find something unique there. Then, all you need to do is to spin a nice story to explain how the pharmacological properties of your drug make it brilliant.
On an entirely unrelated note, aripiprazole (Abilify) is an antipsychotic marketed in the US by Bristol Meyers-Squibb. A Cochrane meta-analysis finds that it’s about as good as any other antipsychotic in terms of efficacy and side effects. As good, but no better. However, uniquely, aripiprazole is a D2 receptor partial agonist. Other antipsychotics work by blocking D2 receptors in the brain, switching them off (full antagonism). Aripiprazole also blocks D2 receptors, but it activates them slightly in the process (partial agonism).
Is that a good thing? A paper just published says yes – The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. The research in question was funded, by the way, by Bristol Meyers-Squibb. Let’s see if it holds up.
Some clean and clear-eyed writing follows, in which Neuroskeptic educates us about dopamine receptors even while exposing a cleverness of study design — the study manages , absurdly but “not unreasonably,” to find a possible lift in well-being without any measured correlations — that comes close to provoking wonder.
“I leave it to the reader to evaluate this claim,” Neuroskeptic concludes, “and to consider how likely we are to progress in our understanding of the brain when so much of the research is funded by organisations with a direct financial interest in certain theories.”